Objective-Basigin (Bsg) is a transmembrane glycoprotein that activates matrix metalloproteinases and promotes inflammation. However, the role of Bsg in the pathogenesis of cardiac hypertrophy and failure remains to be elucidated. We examined the role of Bsg in cardiac hypertrophy and failure in mice and humans. Approach and Results-We performed transverse aortic constriction in Bsg +/and in wild-type mice. Bsg +/mice showed significantly less heart and lung weight and cardiac interstitial fibrosis compared with littermate controls after transverse aortic constriction. Both matrix metalloproteinase activities and oxidative stress in loaded left ventricle were significantly less in Bsg +/mice compared with controls. Echocardiography showed that Bsg +/mice showed less hypertrophy, less left ventricular dilatation, and preserved left ventricular fractional shortening compared with littermate controls after transverse aortic constriction. Consistently, Bsg +/mice showed a significantly improved long-term survival after transverse aortic constriction compared with Bsg +/+ mice, regardless of the source of bone marrow (Bsg +/+ or Bsg +/-). Conversely, cardiac-specific Bsg-overexpressing mice showed significantly poor survival compared with littermate controls. Next, we isolated cardiac fibroblasts and examined their responses to angiotensin II or mechanical stretch. Both stimuli significantly increased Bsg expression, cytokines/chemokines secretion, and extracellular signal-regulated kinase/Akt/JNK activities in Bsg +/+ cardiac fibroblasts, all of which were significantly less in Bsg +/cardiac fibroblasts.
H eart failure is a major cause of death worldwide. 1 Despite the recent development in medical therapy, the morbidity and mortality rate in patients with heart failure remains high and fundamental treatment remains to be developed. Cardiac dysfunction is caused by excessive fibrosis, hypertrophy, and inflammation. 2 Pressure overload, such as systemic hypertension and stenotic valvular heart diseases, induces cardiac hypertrophy. Although cardiac hypertrophy is basically a compensatory response to maintain wall stress and cardiac output, sustained hypertrophic response eventually leads to cardiac dysfunction and failure. 3, 4 To date, the mechanism responsible for transition from adaptive cardiac hypertrophy to failure remains to be elucidated. The responses of cardiac tissues to pressure overload are mediated by various intracellular signaling pathways, including mitogen-activated protein kinase, calcium, inflammation, and oxidative stressmediated signaling pathways. [5] [6] [7] [8] We also have demonstrated that these pathways are substantially involved in the development of heart failure. [9] [10] [11] Basigin (Bsg, also known as CD147 or EMMPRIN, encoded by Basigin) is a transmembrane glycoprotein that is ubiquitously expressed in the body. 12 Bsg is a multifunctional protein that promotes myofibroblast differentiation, cell proliferation, and matrix metalloproteinase (MMP) activation and inhibits autophagy. [13] [14] [15] Bsg is an essential receptor for multiple ligands such as malaria, cyclophilin A (CyPA), and soluble Bsg (sBsg) itself. [16] [17] [18] [19] Bsg promotes progressions of several kinds of malignant tumors and collagen diseases. [20] [21] [22] In the cardiovascular field, Bsg promotes pulmonary hypertension, atherosclerosis, and platelets activation. 15, 16, [23] [24] [25] Bsg also disrupts nitric oxide metabolism and causes harmful endothelial activation, including the Rho/Rho-kinase activation. 26 Importantly, Bsg is highly expressed in the left ventricle (LV) in patients with dilated cardiomyopathy, myocardial infarction, and inflammatory cardiomyopathy. [27] [28] [29] However, the role of Bsg expression in the pathogenesis of heart failure remains to be elucidated.
In this study, we performed transverse aortic constriction (TAC) in both Bsg knockout (Bsg +/-) and cardiomyocyte-specific Bsg-overexpressing mice (Bsg-Tg) to elucidate the role of Bsg in pressure overload-induced heart failure. Here, we report that Bsg +/mice showed resistance to pressure overload and that Bsg-Tg mice showed weakness to pressure overload. Consistently, plasma levels of sBsg was significantly increased in patients with heart failure and well correlated with their long-term survival. Our data suggest that cell surface Bsg and cleaved form of free Bsg (sBsg) are novel therapeutic targets for heart failure.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Bsg in Cardiac Tissue Promotes Cardiac Hypertrophy and Failure
First, we performed TAC in Bsg +/mice and littermate controls (Bsg +/+ mice) to examine the role of Bsg in the progression of pressure overload-induced heart failure. Because complete Bsg disruption in mice results in perinatal lethality, we used Bsg +/mice in this study. At baseline, there was no difference in blood pressure or heart rate between Bsg +/and Bsg +/+ mice ( Figure 1A ). Bsg expression in heart homogenates was reduced by 64% in Bsg +/mice compared with Bsg +/+ mice ( Figure IA in the online-only Data Supplement). Transverse aortic velocities were comparable between Bsg +/+ and Bsg +/mice after TAC ( Figure IB in the online-only Data Supplement). In contrast, survival curves demonstrated a significantly less mortality rate in Bsg +/mice compared with Bsg +/+ mice after TAC ( Figure 1B ). Echocardiographic examination showed that TAC caused LV dilation and dysfunction in both genotypes ( Figure 1C ). TAC caused cardiac hypertrophy as examined by interventricular septum and LV posterior wall thickness in both the genotypes, and the increase in wall thickness was significantly less in Bsg +/compared with Bsg +/+ mice ( Figure 1D ). In addition, the increase in LV internal diameter in diastole and the decrease in LV fractional shortening were significantly less severe in Bsg +/compared with Bsg +/+ mice ( Figure 1D ). Consistently, the measurement of organ weights showed that TAC significantly increased the ratio of heart weight/body weight and lung weight/body weight in both the genotypes ( Figure 1E ). Again, the increase in heart/lung weight ratio was significantly less in Bsg +/compared with Bsg +/+ mice, suggesting that Bsg plays a crucial role in the development of cardiac hypertrophy and failure in response to pressure overload.
Because Bsg plays a crucial role in inflammatory cells that contribute to the development of cardiovascular diseases, we next performed bone marrow (BM) transplantation to examine the role of Bsg in inflammatory cells after TAC. Bsg +/and Bsg +/+ mice were irradiated and thereafter transplanted with BM cells (Bsg +/or Bsg +/+ ). After reconstitution of BM, mice were subjected to TAC and followed for 4 weeks ( Figure IC in the online-only Data Supplement). Importantly, the expression of Bsg was strong in cardiomyocytes and fibrotic tissue but not in green fluorescent protein + transplanted BM (inflammatory cells; Figure ID in the online-only Data Supplement). Moreover, Bsg +/recipient mice were more likely to survive compared with Bsg +/+ recipient mice regardless the source of BM ( Figure IE in the online-only Data Supplement). These data implicated a limited role of Bsg in inflammatory cells of cardiac tissues.
Bsg Augments Pressure Overload-Induced Oxidative Stress and Matrix Metalloproteinase
Because Bsg in cardiac tissue seems to play a crucial role in pressure overloaded heart, we next examined the expression and localization of Bsg in LV after TAC in Bsg +/+ mice by immunofluorescence staining. Bsg was weakly expressed especially in the interstitial tissue at baseline ( Figure 2A ; Figure II in the online-only Data Supplement). In contrast, TAC strongly induced Bsg expression in LV in a time-dependent manner, especially in the surface of cardiomyocytes and fibroblasts. Furthermore, Bsg was significantly glycosylated after TAC compared with SHAM control ( Figure VA in the online-only Data Supplement). Because Bsg is known to induce inflammation and MMP activation, we further evaluated TAC-mediated induction of oxidative stress ( Figure 2B ; Figure III in the online-only Data Supplement) and activation of MMPs ( Figure 2C ; Figure IV in the online-only Data Supplement). Dihydroethidium staining of the LV showed that oxidative stress was induced in both genotypes in a timedependent manner. However, the extent of oxidative stress in the LV was less in Bsg +/compared with Bsg +/+ ( Figure 2B ). In situ zymography (DQ gelatin) showed that MMP activation in the LV was significantly attenuated in Bsg +/compared with Bsg +/+ ( Figure 2C ; Figure IV in the online-only Data Supplement). MMP activities as examined by gelatin zymography were also significantly less in Bsg +/-LV homogenates than in Bsg +/+ LV homogenates ( Figure 2D ). Thus, Bsg plays a crucial role in pressure overload-induced oxidative stress and MMP activation in the LV. 
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Bsg Promotes Cardiac Fibrosis and Inflammation by Pressure Overload
We next performed histological analyses in Bsg +/and Bsg +/+ mice. Elastica-Masson staining demonstrated that TAC induced interstitial fibrosis in the LV of both genotypes ( Figure 3A ). However, the extent of increase was significantly less in Bsg +/compared with Bsg +/+ mice at 4 weeks after TAC ( Figure 3A ). Importantly, immunohistochemistry showed that the expression of CyPA, a potent oxidative stress and inflammation inducer, was increased in Bsg +/+ LVs compared with Bsg +/-LVs after TAC ( Figure 3B ). The expression of CyPA and its receptor, Bsg, was colocalized in the LVs after TAC ( Figure 3B ), suggesting the crucial role of the CyPA/Bsg signaling in the development of cardiac fibrosis and inflammation in pressure overload-induced heart failure. In addition, α-smooth muscle actin expression in the LV was markedly less in Bsg +/compared with Bsg +/+ mice after TAC, suggesting an importance of Bsg for myofibroblast activation and cardiac fibrosis ( Figure 3B ). Consistently, gene expressions of fibrotic markers such as collagen 1a (Col1a) and connective tissue growth factor were significantly less in heart homogenates in Bsg +/compared with Bsg +/+ mice after TAC ( Figure 3C ).
We further examined induction of inflammatory cytokines in response to TAC. Notably, interleukin (IL)-6 expression in the LV after TAC was significantly less in Bsg +/compared with Bsg +/+ mice, though there were no differences in IL-1β and tumor necrotic factor-α ( Figure 3D ). Next, we performed Western blotting to examine the signaling mechanism in Bsg +/+ and Bsg +/− hearts after TAC. However, the activities of extracellular signal-regulated kinase, Akt, and stress-activated protein kinase were comparable between Bsg +/+ and Bsg +/− hearts after TAC ( Figure VB in the online-only Data Supplement). We further examined the Nox expression in hearts after TAC. The Nox2 expression was comparable between Bsg +/− and Bsg +/+ hearts at baseline. However, the expressions of Nox2 was significantly less in Bsg +/− hearts compared with Bsg +/+ hearts 1 week after TAC ( Figure VC and VD in the onlineonly Data Supplement).
Bsg Activates Cardiac Fibroblasts in Response to Mechanical Stretch and Angiotensin II
There was a significant difference in the severity of cardiac fibrosis between Bsg +/and Bsg +/+ mice after TAC. Thus, we harvested cardiac fibroblasts (CFs) from Bsg +/and Bsg +/+ LV and stimulated them with cyclic mechanical stretch (1 Hz, 20% elongation) or angiotensin II (Ang II; 100 nmol/L) for ≤24 hours. Cyclic mechanical stretch-activated protein kinase B (Akt) and stress-activated protein kinase in Bsg +/+ CFs, which was significantly less in Bsg +/-CFs ( Figure 4A ). Interestingly, cyclic mechanical stretch induced Bsg expression in and secretion from CFs, which was significantly less in Bsg +/compared with Bsg +/+ . CyPA secretion was also significantly less in Bsg +/-CFs compared with Bsg +/+ CFs ( Figure 4B ). Because Bsg is known as a strong inducer of inflammation, we next examined the secretion of cytokines/chemokines and growth factors from CFs ( Figure 4C ; Figure VI in the online-only Data Supplement). Importantly, mechanical stretch significantly promoted secretion of several cytokines/ chemokines and growth factors in Bsg +/+ CFs, which was significantly less in Bsg +/-CFs, especially for monocyte chemoattractant protein-1, tumor necrotic factor-α, IL-1, IL-18, and monokine induced by γ-interferon ( Figure 4C ; Figure VI in the online-only Data Supplement). Because pressure overload upregulates Ang II in cardiac tissues, CFs were subjected to Ang II for ≤24 hours. Again, Ang II significantly activated Akt, extracellular signal-regulated kinase and stress-activated protein kinases in Bsg +/+ CFs, which was significantly less in Bsg +/-CFs ( Figure 4D ). Bsg expression and secretion from CFs were significantly less in Bsg +/-CFs compared with Bsg +/+ CFs ( Figure 4E ). In addition, Ang II significantly promoted secretion of cytokines/chemokines and growth factors from Bsg +/+ CFs, which was significantly less in Bsg +/-CFs, especially for IL-6, IL-17, IL-18, tumor necrotic factor-α, and monokine induced by γ-interferon ( Figure 4F and Figure VII in the online-only Data Supplement). These findings suggest that Bsg plays a pivotal role in mediating mechanical stretchand Ang II-induced CFs activation and inflammation. Because we found that both mechanical stretch and Ang II promoted significant secretion of Bsg from CFs, we next examined the role of extracellular Bsg. Human recombinant Bsg (hrBsg) significantly activated Akt and extracellular signal-regulated kinase in Bsg +/+ CFs compared with controls ( Figure 5A ). Moreover, hrBsg induced atrial natriuretic peptide expression in neonatal rat cardiomyocytes (NRCM; Figure 5B ). Furthermore, Bsg knockdown by siRNA significantly reduced Nox2 in neonatal rat CFs ( Figure 5C ). Consistent with these findings, Bsg +/-CFs were significantly less proliferative compared with Bsg +/+ CFs ( Figure 5D ). Because Bsg knockdown significantly reduced the secretion of cytokines/chemokines and growth factors from CFs (Figure 4 ; Figures VI and VII in the online-only Data Supplement), we compared the proliferation of CFs by treatment with conditioned medium. Cell proliferation was significantly promoted by the treatment with conditioned medium, especially by that from Bsg +/+ CFs ( Figure 5E ). We further performed Western blotting of conditioned medium to evaluate the secretion of Although these data demonstrated that Bsg in CFs plays a crucial role in the development of inflammation and heart failure, the responsive Bsg upregulation was especially strong in the cell membrane of cardiomyocytes (Figure 2A ; Figure II in the online-only Data Supplement). Here, to further examine the role of Bsg in cardiomyocytes, we performed TAC in cardiomyocyte-specific Bsg-overexpressing mice (Bsg-Tg). Bsg-Tg mice showed significantly high-Bsg expression in cardiomyocytes ( Figure IXA and IXB in the online-only Data Supplement). Importantly, Bsg-Tg mice showed significantly poor survival compared with littermate controls after TAC ( Figure 5F ). Consistently, echocardiography showed significantly reduced cardiac function in Bsg-Tg mice compared with control mice after TAC in a time-dependent manner ( Figure IXC in the online-only Data Supplement). We further evaluated the proliferation of CFs in Bsg-overexpressing mice in vivo. Interestingly, Elastica-Masson staining of hearts demonstrated that the interstitial fibrotic area in the LVs was significantly increased in cardiomyocyte-specific overexpressing mice (Bsg-Tg) compared with littermate controls after TAC ( Figure 5H) . Moreover, the levels of cytokines/chemokines and growth factors in heart homogenates were elevated in Bsg-Tg mice compared with controls ( Figure X in the online-only Data Supplement), especially for interferon-γ, regulated on activation normal T cell expressed and secreted and basic-fibroblast growth factor ( Figure 5G ). We further performed experiments using NRCM Here, we used the conditional medium from CF in response to cyclic stretch to stimulate NRCMs with or without an inhibitory antibody to Bsg (Bsg-Ab) for ≤24 hours. Interestingly, treatment of NRCM with the inhibitory antibody to Bsg significantly reduced oxidative stress levels assessed by DCF staining compared with controls ( Figure XIC in the online-only Data Supplement). We 
Serum Levels of sBsg Predict Prognosis in Patients With Heart Failure
Because we found that Bsg plays a crucial role in pressure overload-induced heart failure in mice, we next assessed the role of Bsg in patients with heart failure. To confirm the clinical implication of Bsg, we performed cell proliferation assay in human CFs. Treatment with hrBsg significantly increased proliferation of human CFs compared with controls ( Figure 6A) . In contrast, Bsg knockdown by siRNA significantly reduced proliferation of human CFs compared with control siRNA (Figure 6B ). To further examine the clinical implication, we assessed serum levels of sBsg in patients with heart failure. The clinical characteristics and laboratory data of patients with heart failure are shown in Table I in the online-only Data Supplement. Figure 6 . Serum levels of basigin (Bsg) as a novel prognostic biomarker for patients with heart failure. A, Cell proliferation assessed by using Cell Titer 96 MTT assay. Human cardiac fibroblasts (hCFs) were stimulated with human recombinant Bsg (hrBsg: 10 ng/mL) for ≤3 days (n=8 in each group). B, hCFs were transfected with human Bsg siRNA or control siRNA, and cultured for 3 days (n=8 in each group). C, Plasma levels of soluble form of Bsg (sBsg) in patients with heart failure (n=187) compared with healthy controls (n=12). Data are boxand-whisker plots of sBsg (ELISA). D, The Kaplan-Meier curve in patients with high-serum sBsg and those with low-serum sBsg. On the basis of the survival CART analysis, the cut-off points of high-and low-sBsg groups were set at 3099 pg/mL in the composite end point and all-cause death and 2554 pg/mL in heart failure rehospitalization. E, Proposed mechanism of Bsg-mediated cardiac fibrosis and hypertrophy. Cyclic stretch and angiotensin II (Ang II) promote CFs activation and proliferation, which is mediated by cell surface Bsg. Bsg signaling activates Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and stress-activated protein kinase (SAPK) in CFs and induces cell proliferation, oxidative stress, and inflammatory cytokines, resulting in metalloproteinase (MMPs) activation. Extracellular active form of MMPs cleave cell surface Bsg and release sBsg, which interacts with cell membrane Bsg again in an autocrine/paracrine manner. As a result, Bsg forms a vicious cycle to augment proliferation of CFs and inflammatory cytokines secretion. Inflammatory cytokines and sBsg released from CFs stimulate cardiomyocyte hypertrophy and promote cardiac hypertrophy in a paracrine manner. Results are expressed as mean±SEM. CI indicates confidence interval; HF, heart failure; HR, hazard ratio; and ROS, reactive oxygen species. *P<0.05. Importantly, we found significant elevation of sBsg in patients with heart failure compared with healthy controls ( Figure 6C) . Moreover, the elevation of sBsg was severe especially in patients with pressure-overloaded heart disease, such as aortic stenosis and hypertensive heart disease ( Figure XIIA in the online-only Data Supplement). Finally, the event-free survival curve demonstrated that high-sBsg levels were associated with poor prognosis in each end point (composite, all-cause death, and hospitalization for worsening heart failure) in patients with heart failure ( Figure 6D ). These data suggest that Bsg is involved in the pathogenesis of cardiac hypertrophy and heart failure and could be a novel therapeutic target and biomarker for pressure overload-induced cardiac hypertrophy and failure.
Discussion
The major findings of this study are that (1) Bsg is upregulated in pressure-overloaded heart and augments inflammation, MMPs, and oxidative stress; (2) Bsg promotes pressure overloadinduced cardiac fibrosis, hypertrophy, and failure; (3) Bsg in cardiac tissue, but not in inflammatory cells, plays a dominant role for the progression of heart failure; (4) Bsg mediates mechanical stretch-and Ang II-induced activation of CFs and inflammatory cytokines secretion; (5) cell surface Bsg is cleaved and released from CFs and the free sBsg promotes cell proliferation in an autocrine/paracrine manner; (6) serum levels of sBsg are elevated in patients with heart failure and predict their prognosis. On the basis of these findings, we propose that mechanical and neurohumoral stress induce growth-promoting inflammatory responses in cardiac tissue through cell surface and extracellular Bsg with a vicious cycle formation, which could be a novel mechanism for pressure overload-induced cardiac hypertrophy and failure ( Figure 6E ).
Bsg in Cardiac Tissues Promotes Hypertrophy, Fibrosis, and Heart Failure
It has been reported that Bsg is highly expressed in the LV of patients with dilated cardiomyopathy, myocardial infarction, and inflammatory cardiomyopathy. [27] [28] [29] However, the role of Bsg and its signaling in heart failure have been elusive. In this study, we precisely characterized the role of Bsg in pressureoverloaded heart and its basal mechanisms. Cardiac hypertrophy, fibrosis, and inflammation are initially adaptive responses to afterload for maintaining cardiac output. 4, 30, 31 In contrast, excessive cardiac hypertrophy and fibrosis can be a risk factor for sudden cardiac death, poor prognosis, and heart failure hospitalization. 3, 32 Thus, we need to develop a novel therapeutic option for targeting the hypertrophic signaling. 31, 33, 34 In this study, we demonstrated that Bsg is a novel signaling that promotes cardiac hypertrophy, fibrosis, and heart failure in response to pressure overload. These responses were accompanied by significant upregulation of inflammatory cytokines/chemokines and growth factors by Bsg in CFs and cardiomyocytes. Notably, survival rate of mice was significantly improved by Bsg knockdown and worsened by cardiomyocyte-specific Bsg overexpression. It has already been demonstrated that cardiacspecific Bsg-overexpressing mice (Bsg-Tg) show myocardial remodeling and dysfunction in aging mice. 35 Consistent with this report, Bsg-Tg mice showed reduced LV systolic function at baseline and especially after TAC. Moreover, in this study, we demonstrated severe cardiac fibrosis in Bsg-Tg mice after TAC, which is consistent with the previous report that showed increased fibrosis in old Bsg-Tg mice compared with younger mice. 35 In addition, it has been reported that cardiomyocytederived Bsg induces MMPs expressions and activities by oxidative stress and β-adrenergic stimuli. 36 These findings indicate important role of cardiomyocyte-derived Bsg in the development of pressure overload-induced cardiac fibrosis and failure. It is important to elucidate the role of BM-derived Bsg for the development of cardiac hypertrophy and fibrosis. Indeed, it has been reported that Bsg is highly expressed in erythroid cells and white blood cells. 37 However, in this study, immunostaining demonstrated that Bsg expression in green fluorescent protein-positive BM-derived cells was relatively weak compared with that of cardiomyocytes. Thus, we have focused on the role of Bsg in cardiac tissues and used cardiomyocyte-specific Bsg-overexpressing mice. However, further analysis of the role of BM-derived Bsg will provide us important information about the Bsg-mediated inflammation and cardiac fibrosis. Bsg is also called extracellular MMP inducer (EMMPRIN), which indicates an inducer of several kinds of MMPs, 38 and thus potently promotes cardiac remodeling. In this study, TAC upregulated Bsg expression and MMP activities in loaded LV in a time-dependent manner. However, the extent of which was cancelled by Bsg knockdown in mice, suggesting that Bsg plays a crucial role for TAC-induced MMP activation and cardiac remodeling. Thus, inhibition of Bsg signaling could be a novel therapeutic target for heart failure.
Inflammatory Response of CFs to Pressure Overload
It is known that CFs promote cardiac hypertrophy, dysfunction, and inflammation. [39] [40] [41] CFs produce a variety of cytokines, such as IL-6, endothelin-1, and insulin-like growth factor-1, all of which induce hypertrophic response in cardiomyocytes in a paracrine manner. 40, 42, 43 In this study, we demonstrated that cell surface Bsg is cleaved and secreted from CFs in response to stimulus by mechanical stretch and Ang II. Moreover, treatment with hrBsg activated mitogen-activated protein kinase in CFs and promoted cell proliferation. In addition, hrBsg upregulated atrial natriuretic peptide expression in cardiomyocytes. Interestingly, mechanical stretch-mediated secretion of inflammatory cytokines/chemokines and growth factors was also downregulated by Bsg knockdown in CFs, which implicates the role of Bsg as a mechanotransducer in cardiac tissues. These data indicate that sBsg secreted from CFs affects CFs themselves and cardiomyocytes in an autocrine/paracrine manner. Thus, both cell surface Bsg and soluble form of Bsg could be a novel therapeutic target for attenuating cardiac hypertrophy, fibrosis, and failure.
Bsg as a Therapeutic Target and a Novel Biomarker
When we consider Bsg as a novel therapeutic target, there are several compounds for Bsg inhibition. For direct inhibition, there are several reports that demonstrated the role of Bsg monoclonal antibodies to ameliorate atherosclerosis, myocardial infarction, and cancers in mice. 27, 44, 45 For indirect inhibition, berberine, resveratrol, and curcumin have been reported to inhibit Bsg expression through regulation of mitogen-activated protein kinase and reactive oxygen species. [46] [47] [48] [49] In this study, we showed that systemic Bsg inhibition showed resistance to chronic pressure overload in mice in vivo. Thus, inhibition of Bsg could be a promising therapeutic strategy for heart failure.
Next, this study provides novel evidence that serum levels of sBsg are increased in patients with heart failure. In addition, higher sBsg levels predicted all-cause death and heart failure hospitalization. It has been reported that serum levels of sBsg are increased in patients with hepatocellular carcinoma, lupus nephritis, and systemic sclerosis. 21, 50, 51 Moreover, in this study, serum sBsg levels had strong correlations with serum IL-8, monokine induced by γ-interferon , adiponectin, and CyPA, indicating the inflammatory role of Bsg in humans. It has been reported that high levels of serum IL-8 and adiponectin predict poor prognosis in patients with heart failure, 52, 53 which also supports our findings that serum sBsg levels could be a promising biomarker for patients with heart failure. Further study will provide additional knowledge as to the usefulness of sBsg in patients with heart failure.
In conclusions, we were able to demonstrate that Bsg in cardiac tissue plays a crucial role in pressure overload-induced heart failure in mice and patients with heart failure. Bsg could be a novel therapeutic target and a biomarker for heart failure.
Heart failure is a major cause of death and mortality rate still remains high, but fundamental therapies have not been developed yet. Bsg was reported to be upregulated in LV in patients with heart failure; however, the role of Bsg in heart failure remains to be elucidated. In this study, we showed that Bsg deletion improved pressure overload-induced cardiac hypertrophy, fibrosis, and failure in mice through inhibition of MMPs, inflammation, and oxidative stress. Furthermore, we showed that extracellular and intracellular Bsg promoted CFs proliferation and make a vicious cycle to augment cardiac fibrosis in an autocrine and paracrine manner. Furthermore, serum levels of sBsg in patients with heart failure were markedly upregulated and predicted poor prognosis in patients with heart failure. These results provided the evidence that Bsg could be a novel therapeutic target and serum sBsg could be a potential prognostic biomarker for patients with heart failure.
Significance
